Floatz logo

Absk043

Neoplasms

Abbisko Therapeutics Co, LtdPhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

927 Active assets in the Neoplasms cohort.

View all 50

Same molecule, other indications

Absk043 is also rated in:

gastroesophageal cancerDormant
CCC
Indicative ·
53 / 100
View asset →
urothelial carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →